WS-CART-CS1
Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
What's the purpose of the trial?
The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
Accepting patients
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
- WS-CART-CS1 CAR-T therapy is a type of immunotherapy. This type of therapy involves T-cells being taken from the patient and being modified to be able to recognize SLAMF7/CS1 (a protein found on myeloma cells) more easily.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.